Roche to Partner with Regeneron to Increase Supply of COVID-19 Treatment
The collaboration will increase the supply of the potential treatment to at least three and a half times the current capacity.
Roche announced on August 18, 2020 that they are partnering with Regeneron to develop, manufacture, and distribute REGN-COV2, Regeneron’s investigational antiviral antibody combination for the treatment of COVID-19. The collaboration will increase the supply of the potential treatment to at least three and a half times the current capacity.
Through the agreement, the companies will each dedicate manufacturing capacity to the antibody each year while handling their own distribution expenses in their designated territories, a Roche press release said. Both companies will fund Phase III prevention and Phase I healthy volunteer safety studies along with additional global studies to determine the potential for REGN-COV2 in treating or preventing COVID-19.
REGN-COV2 is currently in Phase II/III clinical trials for the treatment of COVID-19 and in a Phase III trial for the prevention of COVID-19 in household contacts of infected individuals, the press release said.
“We are excited about the potential for one medicine to serve both as a treatment for those infected as well as protection for people exposed to the virus. REGN-COV2 could be a critical line of defense against the COVID-19 pandemic,” said Bill Anderson, CEO of Roche, in the press release. “We’re committing our manufacturing expertise and capacity, and our global distribution network to bring Regeneron’s potential antibody combination to as many people around the world as we possibly can.”
“Regeneron has progressed the REGN-COV2 research and development program at record speed and worked tirelessly to maximize our in-house manufacturing capacity,” said Leonard S. Schleifer, MD, PhD, president and CEO of Regeneron, in the press release. “This major collaboration with Roche provides important scale and global expertise to bring REGN-COV2 to many more patients in the United States and around the globe.”
Source: Roche
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.
